Skip to content

ECM1-Mediated Mechanisms Underlying Endometrial Polyp Formation in Endometriosis

ECM1-Mediated Mechanisms Underlying Endometrial Polyp Formation in Endometriosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101442
Enrollment
Unknown
Registered
2025-04-24
Start date
2025-06-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis, Endometrial Polyps

Interventions

Endometriosis & Endometrial Polyps group
EM&EP group:none
Endometrial Polyps group, EP group:none

Sponsors

Shaoxing Maternity and Child Health Care Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1.?Patients diagnosed with endometriosis (EM) via laparoscopy or laparotomy.(test team); 2.?Postoperative pathological confirmation of ectopic endometrial tissue and diagnosis of endometrial polyps (EP) by hysteroscopy.(test team); 3.?No history of hormonal medication use for at least 3 months prior to sample collection.(test team); 4.?Signed informed consent form for the use of human biological tissue specimens in scientific research.(test team); 5.?Patients diagnosed with endometrial polyps ( EP ) by hysteroscopy.( control group ); 6.?Patients with endometrial polyps (EP) confirmed by hysteroscopy, who were excluded from endometriosis (EM) through imaging, laparoscopy, or laparotomy.( control group ); 7.?Postoperative pathological examination confirmed endometrial polyps. ( control group ); 8.?No history of hormonal medication use for at least 3 months prior to sample collection.( control group ); 9.?Signed informed consent form for the use of human biological tissue specimens in scientific research.( control group );

Exclusion criteria

Exclusion criteria: 1.Presence of other systemic diseases or severe comorbidities (e.g., diabetes, hypertension, cardiovascular diseases) potentially affecting study outcomes. 2.Recent (within the past 3 months) history of radiotherapy, chemotherapy, or other treatments significantly affecting the endometrium. 3.Failure to sign the Informed Consent Form for the Use of Human Biological Tissue Specimens in Scientific Research;

Design outcomes

Primary

MeasureTime frame
Related gene mRNA expression levels;Immunohistochemical staining rate of ECM1 pathological sections;

Secondary

MeasureTime frame
In vitro cell function experiments;

Countries

China

Contacts

Public ContactWeicheng Lou

Shaoxing Maternity and Child Health Care Hospital

shushengchengcheng@163.com+86 13777316366

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026